Sharad Khurana is an Oncology physician affiliated with University of Arizona. OpenAlex indexes 41 publications with 234 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3838 N Campbell Ave
Tucson, AZ 857191454
Telephone
520-694-2873Provider last certified this registry record 15 Nov 2024.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20255 payments
- JAZZ PHARMACEUTICALS INC.Program year20251 payment
- Incyte CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
39.9%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.9%Valacyclovir100%Part D≥22 patientsShort-acting sulfonamides8.8%Sulfamethoxazole-Trimethoprim100%Part D≥13 patients+ 5 more classes in this area
Cancer & immunology
23.6%BCL-2 Inhibitor8.2%Venclexta100%Part D≥22 patientsAntimetabolite6.2%Hydroxyurea100%Part D≥14 patients+ 2 more classes in this area
Dermatology
12%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor12%Acyclovir100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical and Immunologic Correlates of out-of-Specification Ciltacabtagene Autoleucel in Multiple Myeloma: A University of Arizona Analysis
Biology of Blood and Marrow Transplantation
2026 - Real-World Safety, Efficacy, and Immune Recovery Following Out-of-Specification Ciltacabtagene Autoleucel in Multiple Myeloma
Biology of Blood and Marrow Transplantation
2026 - Outpatient administration of CAR T-cell therapy: A University of Arizona Cancer Center experience.
Journal of Clinical Oncology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Alpert, MD
University of Arizona
Karl Kern, MD
University of Arizona
Peter Reaven, MD
University of Arizona
Alison Stopeck, MD
University of Arizona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”